NasdaqGS:RGENLife Sciences
Is Repligen (RGEN) Still Undervalued Following Its $1.5b BioLife Deal?
Repligen (RGEN) has agreed to acquire BioLife Solutions in a roughly $1.5 billion deal, a move that immediately shifts investor focus to how a larger cell therapy footprint could influence the stock’s risk and reward profile.
See our latest analysis for Repligen.
Repligen’s share price has been volatile, with a 22.82% 90 day share price return and a 10.68% 30 day share price return contrasting with a decline of 14.76% year to date, while the 1 year total shareholder return of 19.60% hints at...